Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells

Therapeutic potential of a peptide targeting BCL-2 cell guardians in cancer

(2012) Jerry M. Adams   JOURNAL OF CLINICAL INVESTIGATION

Abnormal expression of FLI1 protein is an adverse prognostic factor in acute myeloid leukemia

(2011) S. M. Kornblau et al.   BLOOD

p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1 -mediated down-regulation of CXCL12

(2011) K. Kojima et al.   BLOOD

TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome

(2011) F. G. Rucker et al.   BLOOD

Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737

(2011) Kensuke Kojima et al.   CANCER

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

(2011) Andrew W. Roberts et al.   JOURNAL OF CLINICAL ONCOLOGY

Variable slope normalization of reverse phase protein arrays

(2009) E. Shannon Neeley et al.   BIOINFORMATICS

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

(2009) Pierre Fenaux et al.   JOURNAL OF CLINICAL ONCOLOGY

Functional proteomic profiling of AML predicts response and survival

(2008) S. M. Kornblau et al.   BLOOD

Hypomethylation and apoptosis in 5-azacytidine–treated myeloid cells

(2008) Rasheed Khan et al.   EXPERIMENTAL HEMATOLOGY

The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML

(2008) K Kojima et al.   LEUKEMIA

Bcl-2 family proteins and cancer

(2008) K W Yip et al.   ONCOGENE